Bioworld: Abbisko’s pimicotinib meets endpoints in phase III

Nov 13,2024

PharmaBoardroom interviews Dr. Xu Yaochang, the founder and CEO of Abbisko

Jul 17,2024

Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal

Dec 12,2023

Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug

Dec 05,2023

FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront

Dec 05,2023

Bioworld: Abbisko reports first-in-human data for homegrown FGFR4 inhibitor and PD-L1 inhibitor

Oct 18,2023

TIME: The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial.

Mar 17,2023

HEALTHY GEM：Abbisko Therapeutics Announces An Out-License Agreement With Allist For ABK3376

Mar 17,2023

Bioworld：FDA grants breakthrough therapy designation to Abbisko's CSF­ 1R inhibitor, pimicotinib

Jan 30,2023

Bioworld：Abbisko out-licenses preclinical EGFR candidate to Allist for $188M

Mar 03,2023

AP NEWS: Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Jan 31,2023

TIME: Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD

Jan 19,2023

Abbisko Therapeutics Obtained ABSK091 IND Approval from NMPA

Dec 14,2020

Abbisko Therapeutics’ Partner X4 Pharmaceuticals Presented Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome

Jun 19,2020

Abbisko Therapeutics Completes Dosing of the First Patient Cohort for ABSK-021 and The First Patient Enrollment for ABSK-011

Apr 07,2020

Abbisko Therapeutics Enters into Licensing Agreement with AstraZeneca for Development and Commercialization of AZD4547

Nov 08,2019